Money talks: Verastem leverages IPO to build cancer stem cell pipeline
This article was originally published in Scrip
Executive Summary
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.